Scholarlink

<p>Protein glycosylation has been implicated in the pathogenesis of cancer, with colorectal cancer (CRC) strongly associated with serum N-glycosylation and IgG N-glycosylation. However, the N-glycosylation profile of non-immunoglobulin serum proteins (IgS-D) in CRC progression remains largely unexplored. Serum IgS-D was isolated using affinity chromatography, followed by the release of N-glycans, methylamidation, and MALDI-MS analysis. The potential of the IgS-D N-glycome profile to reflect CRC progression was assessed through Mann-Whitney U tests and multivariate analysis. A total of 43 distinct N-glycans were identified in IgS-D. Notably, a significant reduction in serum IgS-D mannosylated N-glycans was observed in CRC patients compared to healthy controls. Further analysis of individual N-glycans revealed significant differences and diagnostic potential in five specific N-glycans: H5N2 (AUC = 0.868), H6N2 (AUC = 0.73), H5N4S1 (AUC = 0.800), H5N5S1F1 (AUC = 0.713), and H5N4S2F1 (AUC = 0.689). A panel comprising these five N-glycans demonstrated high diagnostic accuracy for CRC (AUC = 0.924). The N-glycosylation profile of serum IgS-D is closely associated with CRC progression. Specific N-glycan signatures provide robust discrimination between CRC patients and healthy controls, warranting further investigation into the underlying molecular mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

N-glycan signatures of immunoglobulins-depleted serum proteins in colorectal cancer

  • 期刊论文

  • 发表日期：

    2026年4月23日

查看全文
  • Huiai Lu,
  • Yuanyuan Liu,
  • Yi Wang,
  • Jiajing Lin,
  • Liming Cheng,
  • Xin Liu,
  • Si Liu,
  • at

摘要

Protein glycosylation has been implicated in the pathogenesis of cancer, with colorectal cancer (CRC) strongly associated with serum N-glycosylation and IgG N-glycosylation. However, the N-glycosylation profile of non-immunoglobulin serum proteins (IgS-D) in CRC progression remains largely unexplored. Serum IgS-D was isolated using affinity chromatography, followed by the release of N-glycans, methylamidation, and MALDI-MS analysis. The potential of the IgS-D N-glycome profile to reflect CRC progression was assessed through Mann-Whitney U tests and multivariate analysis. A total of 43 distinct N-glycans were identified in IgS-D. Notably, a significant reduction in serum IgS-D mannosylated N-glycans was observed in CRC patients compared to healthy controls. Further analysis of individual N-glycans revealed significant differences and diagnostic potential in five specific N-glycans: H5N2 (AUC = 0.868), H6N2 (AUC = 0.73), H5N4S1 (AUC = 0.800), H5N5S1F1 (AUC = 0.713), and H5N4S2F1 (AUC = 0.689). A panel comprising these five N-glycans demonstrated high diagnostic accuracy for CRC (AUC = 0.924). The N-glycosylation profile of serum IgS-D is closely associated with CRC progression. Specific N-glycan signatures provide robust discrimination between CRC patients and healthy controls, warranting further investigation into the underlying molecular mechanisms.